SMT Mobile Menu


CETP Inhibition Raises HDL and Postprandial Insulin Concentration

CETP Inhibition Raises HDL and Postprandial Insulin Concentration

Elevating high-density lipoprotein cholesterol (HDL) levels via cholesteryl ester transfer protein (CETP) inhibition increases postprandial plasma insulin concentration, according to this randomized double-blind study of healthy volunteers. The authors speculate that raising HDL via CETP inhibition may improve beta-cell function and postprandial insulin secretion in those with type 2 diabetes mellitus as well. Editorialists say these results support the notion that short-term exposure to a CETP inhibitor produces the expected large changes in HDL and low-density lipoprotein levels and influences glucose metabolism in many ways.

RESULT:  Effects of High-Density Lipoprotein Elevation With Cholesteryl Ester Transfer Protein Inhibition on Insulin Secretion
Circulation Research | Jul 5, 2013 (FREE FULL TEXT)

RESULT:  Killing Two Birds With One Stone, Maybe 
Circulation Research | Jul 5, 2013 (FREE FULL TEXT)

Genetic variation in the CETP gene is consistent with a protective effect of CETP inhibition on risk of ischemic events and on total mortality, according to an examination of a prospective cohort study. The authors found that genetic CETP inhibition was associated with reductions in risk of ischemic heart disease, myocardial infarction, ischemic cerebrovascular disease, and ischemic stroke, with a corresponding anti-atherogenic lipid profile, and with increased longevity without adverse effects.

Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects
Journal of the American College of Cardiology | Nov 13, 2012 (Free abstract. Full text $15)

Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.